Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Open-label Pharmacokinetic, Efficacy and Safety Study of rVIII-SingleChain in a Pediatric Population With Severe Hemophilia A

NCT02093897 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT02093897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02093897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Open-label Pharmacokinetic, Efficacy and Safety Study of rVIII-SingleChain in a Pediatric Population With Severe Hemophilia A
Lead sponsor
CSL Behring
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2014
Completion date
August 31, 2015
Enrollment
84 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

congenital hemophilia a